Aspirin has been the cornerstone of CAD treatment for decades, to which, after ACS, a P2Y12 inhibitor is added to further reduce major adverse cardiac events (MACE, namely cardiovascular death, MI, and stroke) [12]. This evidence concerns the gene P2RY12 and coronary artery disorder.